Eli Lilly and Company (LLY)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Operating income | US$ in thousands | 3,024,300 | 316,700 | 564,300 | -483,600 | -138,600 |
| Total assets | US$ in thousands | 78,714,900 | 64,006,300 | 49,489,800 | 48,806,000 | 46,633,100 |
| Operating ROA | 3.84% | 0.49% | 1.14% | -0.99% | -0.30% |
December 31, 2024 calculation
Operating ROA = Operating income ÷ Total assets
= $3,024,300K ÷ $78,714,900K
= 3.84%
Eli Lilly and Company's operating return on assets (ROA) has shown a fluctuating trend over the years. As of December 31, 2020, the company reported a negative operating ROA of -0.30%, indicating that its operating income generated from its assets was inefficient. This negative trend worsened in the following year, with a lower operating ROA of -0.99%.
However, the company's performance improved significantly in December 31, 2022, with an operating ROA of 1.14%, signifying a turnaround in utilizing its assets more effectively to generate operating income. This positive momentum continued into December 31, 2023, with a 0.49% operating ROA.
In December 31, 2024, Eli Lilly and Company demonstrated substantial improvement in its operating ROA, reaching 3.84%. This surge indicates that the company enhanced its operational efficiency in utilizing its assets to generate operating income, suggesting better profitability and asset management.
Overall, the analysis of Eli Lilly and Company's operating ROA reflects a mix of challenges and improvements in optimizing asset utilization for generating operating income over the years.
Peer comparison
Dec 31, 2024